degree relatives (Ghadirian et al, 1991; Lynch et al, 1992) . These observations suggest an inherited predisposition to these cancer types in a subset of patients, but the genes that underlie this genetic susceptibility remain largely unknown. Clustering of ovarian and gastric cancer (Easton et al, 1996) and breast/ovarian and exocrine pancreatic cancer (Tulinius et al, 1992) have been reported, suggesting a role for BRCA2 gene mutations in pancreatic cancer predisposition (Phelan et al, 1996) . Furthermore, a large study encompassing more than 3000 BRCA2 mutation carriers and their first-degree relatives, estimated the relative risk (RR) for developing cancers other than breast/ovarian: for pancreatic cancer the RR was 3.51, for gallbladder and bile duct cancer -4.97 and for stomach cancer -2.59 (BCLC, 1999) .
Among Jewish people, a single predominant mutation within the BRCA2 gene (6174delT) occurs. This mutation can be detected in individuals at risk for developing breast and ovarian cancer (Abeliovich et al, 1997) , in about 1-1.5% of the general Ashkenazi (East European) Jews (Ouddoux et al, 1996; Roa et al, 1996) , and rarely among non-Ashkenazi Jews . Analysis of 245 unselected patients with pancreatic cancer for this mutation, revealed two mutation carriers (0.8%) and an additional BRCA2 germline mutation carrier in a nearby codon (Goggins et al, 1996) . However, not all patients in this latter study were Jewish individuals. Direct mutational analysis of 39 unselected Jewish Ashkenazi patients with pancreatic cancer, revealed 4 6174delT BRCA2 (10%) mutation carriers (Ozcelik et al, 1997) .
To test the notion that BRCA2 mutations predispose to gastrointestinal malignancies other than colorectal cancer, we determined the rate of the BRCA2 6174delT predominant germline mutation in Summary Inherited predisposition occurs in 5-10% of all gastrointestinal (GI) cancer patients, but with the exception of colorectal cancer (CRC), the genes involved in conferring genetic susceptibility remain largely unknown. Indirect evidence indicates that germline mutations in BRCA2 might be associated with an increased risk for various GI malignancies. A single mutation (6174delT) occurs in the BRCA2 gene in high-risk breast ovarian cancer families of Jewish Ashkenazi origin, in about 1% of the general Ashkenazi population, and rarely in nonAshkenazi Jews. In order to assess the contribution of this germline mutation to non-CRC GI cancer in Jewish Israeli patients, we tested 70 unselected, consecutive Jewish Ashkenazi patients with gastrointestinal malignancies for this mutation by PCR amplification and modified restriction enzyme digests. Patients' age range was 38-90 years (mean 65.8±11.8 years). The most common malignancies were gastric cancer (n = 35) and exocrine pancreatic cancer (n = 23). Overall, 6 mutation carriers were detected: 3/23 (13%) of the patients with pancreatic cancer, 2/35 (5.7%) of patients with gastric cancer and 1/4 (25%) of patients with bile duct cancer. The 8.6% mutation carrier rate among patients is a rate significantly higher than that of the general Ashkenazi population (1.16% P = 0.0002). We conclude that the rate of the predominant Jewish BRCA2 mutation in patients with gastric and pancreatic cancer significantly differ from that of the general population of the same ethnic origin. Thus, BRCA2 mutations probably contribute to gastrointestinal tumorigenesis other then colon cancer, and the surveillance scheme for mutation carriers should incorporate this information. © 2001 Cancer Research Campaign http://www.bjcancer.com Keywords: BRCA 2; Jewish founder mutation; non-colon cancer; inherited predisposition to cancer 70 unselected Jewish Ashkenazi patients with these types of malignancies who were consecutively treated in a single medical centre in Israel.
MATERIALS AND METHODS

Patients' characteristics and tumour material
All patients with a clinical and histopathological diagnosis of gastrointestinal malignancy (excluding colorectal cancer) who were treated at the Institute of Oncology, Rabin Medical Center from January 1, 1999 to March 31, 2000, were eligible for participation. The study was approved by the institutional review board, and all patients signed an informed consent. All consenting patients filled a detailed questionnaire that includes demographic data, past medical history, age at diagnosis, family history of cancer, especially gastrointestinal, breast and/or ovarian. Based on the criteria applied for other familial cancers, patients having at least one first-degree relative with GI or BRCA2 related cancer (breast and ovarian), or more than two second-degree relatives with cancer one of which is of GI, breast or ovarian origin, were classified as familial cases.
DNA extraction
Anticoagulated peripheral blood was withdrawn by venopuncture, and DNA was extracted using standard techniques, using the Gentra kit (Gentra Inc., Minneapolis, MN).
Mutation analysis of the predominant Jewish mutation in BRCA2
Mutational analyses for the predominant mutation (6174delT) in BRCA2, were carried out by restriction enzyme digest of amplified PCR products using modified amplification primers, to generate novel restriction sites, followed by restriction enzyme analysis to distinguish the mutant from the wild-type allele, as previously described (Rohlfs et al, 1997) , and adopted by us (Bar Sade et al, 1998) .
Statistical analyses
Comparison of the rates of the founder Jewish mutation in BRCA2 between the general Jewish Ashkenazi population (Hartage et al, 1999) and all GI cancer patients in our study group as well as the distribution within specific tumour types were performed using Fisher's Exact test. Odds ratio (OR) and the 95% confidence intervals (CI) were calculated from the tables Even though the numbers for the Jewish Ashkenazi population are based on American Ashkenazi Jews (Hartage et al, 1999) , we assumed that it is legitimate to use these numbers for two main reasons: first, the Ashkenazi Jewish population is well characterized as a distinct ethnic entity, regardless of the present place of residence (i.e. Tel-Aviv or Washington). Second, comparisons of Israeli and non-Israeli Ashkenazis with regard to being 185delAG BRCA1 mutation carriers, did not show any differences between Israelis and Americans (Streuwing et al, 1997).
RESULTS
Patients' characteristics
All 70 were of Ashkenazi origin. The most common malignancy was gastric cancer (n = 35), followed by exocrine pancreatic cancer (n = 23), oesophageal cancer (n = 7), bile duct cancer (n = 4) and one small bowel cancer. Median age at diagnosis was 67 years (range 38-90 years) with a mean age of 65.8±11.8 years; 6 patients (8.57%) were diagnosed between 38-49 years; 16 (22.8%) -between 50-59 years; 19 (27.2%) -between 60-69 years; 20 (28.6%) -between 70-79 years; 9 (12.8%) over the age of 80 years. 13 (18.5%) and 12 (17.1%) patients had first-degree relatives with gastrointestinal or other cancer, respectively, and 4 (5.7%) had at least one first-degree relative with breast cancer.
Germline mutational analysis
The presence of 6174delT BRCA2 germline mutation was tested in all study participants and 6 carriers were found (6/70-8.6%). The clinical and pertinent data of the 6 mutation carriers are presented in Table 1 . Notably, 3/23 of the patients with pancreatic cancer (13%), 2/35 (5.7%) of the patients with gastric cancer and 1/4 of the patients (25%) with bile duct cancer were mutation carriers. Surprisingly, only 1/5 individuals with a family history of breast and/or ovarian cancer was among the mutation carriers, and family history of other cancer was ascertained in 4/6 mutation carriers (Table 1 ). In addition, the age at diagnosis in mutation carriers was not noticeably younger than other individuals with the same cancer type.
Statistical analyses
There was a statistically significant difference in the carrier rate of the 6174delT BRCA2 mutation between the general Jewish Ashkenazi population and all cancer types in the present study combined (59/5089 vs. 6/70, P = 0.0002). Analysis of the rate of this mutation within specific tumour types, showed that the rates in pancreatic cancer and bile duct cancer were also statistically significant higher than population controls (Table 2) .
DISCUSSION
In the present study, the involvement of the BRCA2 gene in inherited predisposition to gastrointestinal cancer other than colorectal cancer was evaluated by direct mutational analysis. The rate of the predominant Jewish mutation in BRCA2 in Ashkenazi patients with gastric, exocrine pancreatic cancer and bile duct cancer was significantly greater than the rate in the general Jewish Ashkenazi population (Struewing et al, 1997; Hartage et al, 1999) . Furthermore, family history of cancer was elucidated in 4/6 mutation carriers, as an additional evidence that the mutation found is not merely an incidental finding, but rather reflects a true inherited predisposition.
The data presented herein are in agreement with other studies showing a higher than expected rate of BRCA2 gene germline mutations in pancreatic cancer in ethnically diverse populations, and in Ashkenazi Jews, in particular. The original observation regarding finding of 2/245 (0.8%) 6174delT mutation carriers and 4/39 (10%) among unselected patients (Goggins et al, 1996) or Jewish individuals (Ozelick et al, 1997) with pancreatic cancer has been mentioned. Analysis of 38 Jewish individuals with pancreatic cancer, revealed 3 (7.9%) BRCA2 6174delT mutation carriers (Lal et al, 2000) . Furthermore, in Iceland, where a single predominant mutation (999del5) in BRCA2 exists, first-degree relatives of mutation carriers had a higher than expected rate of pancreatic cancer (Thorlacius et al, 1997) . The role of BRCA2 mutations in conferring genetic susceptibility to gastric, oesophageal, hepatic and biliary tract cancer is much less established. A high rate of allelic loss at the BRCA2 locus has been reported, but few somatic mutations have been detected in BRCA2 in hepatocellular cancer (Katagiri et al, 1996) . Similarly, 93% of oesopahgeal cancer from patients with a family history of the disease (n = 23), displayed allelic loss with a marker from the long arm of chromsome 13 (D13S894) (Hu et al, 1999) . Moreover, in the most comprehensive study of cancer types other than breast and ovarian, associated with germline BRCA2 mutations, up to five-fold increased risk for biliary tract and more than double the risk for stomach cancer is reported (BCLC, 1999) . However, to the best of our knowledge, no direct mutational analyses studies were ever performed in individuals with these latter cancer types.
The results of the present study which support other lines of indirect evidence as to the involvement of BRCA2 germline mutations in the susceptibility to cancer of the upper gastrointestinal tract, should be reflected in genetic counselling. The increased risk for developing these malignancies should be incorporated into the routine counselling process, and surveillance schemes aimed at early detection of these cancer types should be devised and tested. Furthermore, the subset of Ashkenazi Jewish patients with either gastric, pancreatic cancer or bile duct cancer and a strong family history of cancer should probably all be tested for being BRCA2 mutation carriers.
In conclusion, in Jewish individuals, germline mutations in the BRCA2 gene seem to contribute to the genetic susceptibility to gastric, exocrine pancreatic and/or biliary tract cancer, and a family history of these or related cancer types. The predictive value, penetrance and the lifetime risk for developing these neoplasms in Jewish BRCA2 mutation carriers remains to be determined in a larger, prospective study.
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